-1752955116519.webp&w=3840&q=75)
2025 NOSCM | Novel Immunotherapy and ADCs in Bladder Cancer Management
Overview
Dr. Vadim Koshkin discussed bladder cancer advances, noting the NIAGARA trial showed improved survival with durvalumab + chemo in muscle-invasive disease. Enfortumab vedotin + pembrolizumab outperformed chemo in metastatic cases. HER2-targeted ADCs and future ADC-checkpoint combos show promise.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Vadim Koshkin, MD
Date of Release
July 20th, 2025
-1755991286446.webp&w=3840&q=75)
-1755991157601.webp&w=3840&q=75)